Eli Lilly and Company officially announced its definitive agreement to acquire Dermira in January 2020 and successfully completed the multi-billion-dollar all-cash transaction in February 2020. Through this strategic buyout valued at approximately $1.1 billion, Eli Lilly secured full global ownership of Dermira's late-stage immunology pipeline—including lebrikizumab for atopic dermatitis—as well as its commercialized topical products, fully incorporating the company into its expanding specialty therapeutic division.